Ad
related to: anti ischemic medical therapy
Search results
Results From The WOW.Com Content Network
Trimetazidine is described as the first cytoprotective anti-ischemic agent developed and marketed by Laboratoires Servier (France). It is an anti-ischemic (antianginal) metabolic agent of the fatty acid oxidation inhibitor class, meaning that it improves the heart muscle's ability to use glucose as a fuel by inhibiting its use of fatty acid ...
Antiplatelet medications are one of the primary recommendations for treatment of both stable [4] and unstable [5] ischemic heart disease.Most commonly, aspirin is used as a single medication in cases of uncomplicated stable angina, and in some cases of unstable angina.
An antianginal is a drug used in the treatment of angina pectoris, a symptom of ischaemic heart disease. Myocardial ischemia arises from the dysfunction of coronary macrovascular or microvascular components, leading to a compromised supply of oxygen and nutrients to the myocardium. The underlying pathophysiological mechanisms encompass a range ...
Information card published by the National Heart, Lung, and Blood Institute urging people with symptoms of angina to call the emergency medical services.. Because of the relationship between the duration of myocardial ischemia and the extent of damage to heart muscle, public health services encourage people experiencing possible acute coronary syndrome symptoms or those around them to ...
Primarily distributed in Eastern Europe, meldonium is used as an anti-ischemia medication. [1] Meldonium is prescribed for cardiovascular, neurological, and metabolic conditions due to its anti-ischaemic and cardioprotective effects, achieved by inhibiting β-oxidation and activating glycolysis. Athletes have used meldonium to enhance recovery ...
[1] [2] Antithrombotics can be used therapeutically for prevention (primary prevention, secondary prevention) or treatment of a dangerous blood clot (acute thrombus). In the U.S., the American College of Chest Physicians publishes clinical guidelines for clinicians for the use of these drugs to treat and prevent a variety of diseases.
Dabigatran is an oral direct thrombin inhibitor. Dabigatran (Pradaxa) was found to be noninferior to Warfarin in prevention of ischemic stroke, as well as intracranial hemorrhage risk and overall mortality for non-valvular atrial fibrillation according to the RE-LY trial. [9]
However, many patients who were eligible for treatment were not treated. [14] [15] tPA has also been given to patients with acute ischemic stroke above age 90 years old. Although a small fraction of patients 90 years and above treated with tPA for acute ischemic stroke recover, most patients have a poor 30-day functional outcome or die. [16]